Atomo Diagnostics (AT1) Q2 2025 earnings summary

Executive summary

• Secured a AUD 440,000 ($440k) government-funded HIV self-test order in Australia, reflecting strong public health demand.

• Executed an Australian Government CRC-P grant for syphilis test development, with the first payment received and project activities underway; total grant value $2.44M.

• Unaudited Q2 FY25 revenue reached AUD 1.2 million ($1.2m), bringing H1 revenue to AUD 2.1 million (~$2.1m).

• Cash receipts for Q2 were AUD 1.7 million ($1.7m), supplemented by R&D ATO rebate ($753k) and nearly AUD 500,000 ($485k) from the CRC-P grant.

• Ended Q2 with AUD 2.9 million ($2.9m) cash on hand, up from AUD 2.6 million in Q1, and remains debt-free.

Financial highlights

• Q2 FY25 revenue: AUD 1.2 million ($1.2m); H1 FY25 revenue: AUD 2.1 million (~$2.1m).

• HIV test sales in Q2: $790k; Pascal OEM sales: $370k; remainder from development and grants.

• Operating costs for H1: AUD 3.4 million ($3.4m), down from AUD 3.7 million ($3.7m) year-over-year.

• Cash receipts for Q2: AUD 1.7 million ($1.7m); total cash inflow including grants and rebates: approx. AUD 3 million ($3m).

• Payments to directors in Q2: $195k in salaries and fees.

Outlook and guidance

• Continued growth expected in HIV self-test sales in Australia, with expansion into pharmacy and vending machine channels.

• Anticipates growth in Europe via a five-year, AUD 5 million (A$5.44m) contract with Newfoundland Diagnostics, and expansion into South America and New Zealand.

• Strategic focus on private sector channels in LMICs for better pricing and scalability.

• Plans to lobby for policy changes to allow at-home HIV testing for PrEP users in Australia.

• Syphilis test development progressing, with clinical trials and regulatory submissions planned for Australia, Europe, and the U.S.